The ongoing study, presented at the San Antonio Breast Cancer Symposium, enrolled 196 women and sequenced circulating tumor DNA in 142 ...
News
- SABCS: Foundation's blood test predicts early relapses in triple-negative breast cancer
- Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio ...
13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), ... a poster at the AACR San Antonio Breast Cancer Symposium in San Antonio, ...
- BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®
(“BriaCell” or the “Company”) (TSXV:BCT, OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for ...
- plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer
... at the 2019 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, .... NERLYNX is a registered trademark of Puma Biotechnology, Inc.
- BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®
V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce ...